Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: Results of a multicenter study

Table 1 ASCA detected in CrD and UC patient groups and HBD: frequency of IgA and/or IgG isotype

ASCA + isotype	CrD (n = 54)	UC (n = 4)	HBD (n = 2)
IgA and IgG	22	1	1
IgA and not IgG	23	2	0
IgG and not IgA	9	1	1

ASCA: anti-Saccharomyces cerevisiae antibodies; CrD: Crohn’s disease; HBD: healthy blood donors.

Table 2 Study of the correlation between clinical features of CrD and detection of ASCA

Clinical features of CrD	Numberof patients	Number of patientspositive for ASCA (%)	P
Age at diagnosis			< 0.001
≤ 20 yr	47	34 (72)
> 20 yr	58	20 (34)
Disease activity			NS
Quiescent	29	10 (34)
Active	71	40 (56)
Disease location			NS
Small bowel	17	11 (65)
Colon	28	10 (36)
Small bowel and colon	49	25 (51)
Anal complications			< 0.001
Presence	31	22 (71)
Absence	63	22 (35)
Extra intestinal manifestations			NS
Presence (except pancreatitis)	45	19 (42)
Pancreatitis	14	6 (43)
Absence	45	23 (51)

NS: no statistically significant difference; CrD: Crohn’s disease; ASCA: anti Saccharomyces cerevisiae antibodies. The total number of patients is different in each clinical feature because patients with one or two unknown items were nevertheless included.

Table 3 Study of the correlation between therapeutic modalities of CrD and detection of ASCA

Treatment of CrDpatients	Number of patients	Number of positivepatients for ASCA (%)	P
Medical treatment			NS
Corticosteroids	27	15 (55)
Immunosuppressive	19	8 (42)
Drugs (IS)
Corticosteroids + IS	18	10 (55)
Other treatment	25	9 (36)
No treatment	11	5 (45)
Surgical treatment			NS
Presence	21	11 (52)
Absence	79	40 (51)

NS: no statistically significant difference; CrD: Crohn’s disease; ASCA: anti-Saccharomyces cerevisiae antibodies. The total number of patients is different in each clinical feature because patients with one or two unknown items were nevertheless included.

Table 4 Study of the correlation between clinical features and therapeutic modalities of CrD and detection of PAB

Clinical featuresof CrD	Numberof patients	Number of patientspositive for PAB (%)	P
Age at diagnosis			0.028
≤ 20 yr	47	25 (53)
> 20 yr	58	18 (31)
Disease activity			NS
Quiescent	29	14 (48)
Active	71	27 (38)
Disease location			NS
Small bowel	17	6 (35)
Colon	28	14 (50)
Small bowel and colon	49	19 (39)
Anal complications			NS
Presence	31	17 (55)
Absence	63	22 (35)
Extra intestinal manifestations			NS
Presence (except pancreatitis)	45	16 (36)
Pancreatitis	14	7 (50)
Absence	45	21 (47)
Medical treatment			NS
Corticosteroids	27	8 (30)
Immunosuppressive drugs (IS)	19	8 (42)
Corticosteroids + IS	18	10 (55)
Other treatment	25	12 (48)
No treatment	11	5 (45)
Surgical treatment			NS
Presence	21	7 (33)
Absence	79	35 (44)

NS: No statistically significant difference; CrD: Crohn’s disease; PAB: Anti-pancreatic antibodies. The total number of patients is different in each clinical feature because patients with one or two unknown items were nevertheless included.